Next Article in Journal
Nerve Growth Factor (NGF)—Receptor Survival Axis in Head and Neck Squamous Cell Carcinoma
Next Article in Special Issue
Anti-Inflammatory Effects of Resveratrol: Mechanistic Insights
Previous Article in Journal
Synergistic Antitumor Effect of Oligogalacturonides and Cisplatin on Human Lung Cancer A549 Cells
Previous Article in Special Issue
Astragalus membranaceus Extract Attenuates Inflammation and Oxidative Stress in Intestinal Epithelial Cells via NF-κB Activation and Nrf2 Response
Article

Farrerol Relieve Lipopolysaccharide (LPS)-Induced Mastitis by Inhibiting AKT/NF-κB p65, ERK1/2 and P38 Signaling Pathway

College of Veterinary Medicine, Jilin University, Changchun 130062, China
*
Authors to whom correspondence should be addressed.
These authors contributed equally to this work.
Int. J. Mol. Sci. 2018, 19(6), 1770; https://doi.org/10.3390/ijms19061770
Received: 14 May 2018 / Revised: 7 June 2018 / Accepted: 9 June 2018 / Published: 14 June 2018
(This article belongs to the Special Issue Natural Anti-Inflammatory Agents 2018)
Farrerol has been proved to have an anti-inflammatory effect. However, the effects of farrerol on mastitis have not been investigated. This study was aimed to investigate the effect and mechanism of farrerol in lipopolysaccharide (LPS)-induced mouse mastitis and LPS-induced inflammatory response of mouse mammary epithelial cells (mMECs). In vivo, LPS were injected to the tetrad pair of nipples for establishing mouse mastitis, and then tested the effect of farrerol on histopathological changes, inflammatory response and activation degree of protein kinase B (AKT), nuclear factor-kappa B p65 (NF-κB p65), p38, extracellular regulated protein kinase (ERK1/2). In vitro, the mMECs were incubated by farrerol for 1 h following by stimulating with LPS, and then the inflammatory response and the related signaling pathways were detected. The in vivo results found that farrerol could improve pathological injury of mammary gland, attenuate the activity of myeloperoxidase (MPO), inhibit the production of pro-inflammatory mediators and the phosphorylation of AKT, NF-κB p65, p38 and ERK1/2. The in vitro results also found farrerol inhibited inflammatory response and the related signaling pathways. Collectively, this study revealed that farrerol inhibits the further development of LPS-induced mastitis by inhibiting inflammatory response via down regulating phosphorylation of AKT, NF-κB p65, p38, and ERK1/2. These findings suggest that farrerol may be used as an anti-inflammatory drug for mastitis. View Full-Text
Keywords: mastitis; farrerol; LPS; NF-κB; Mitogen-activated protein kinase (MAPK) mastitis; farrerol; LPS; NF-κB; Mitogen-activated protein kinase (MAPK)
Show Figures

Graphical abstract

MDPI and ACS Style

Li, Y.; Gong, Q.; Guo, W.; Kan, X.; Xu, D.; Ma, H.; Fu, S.; Liu, J. Farrerol Relieve Lipopolysaccharide (LPS)-Induced Mastitis by Inhibiting AKT/NF-κB p65, ERK1/2 and P38 Signaling Pathway. Int. J. Mol. Sci. 2018, 19, 1770. https://doi.org/10.3390/ijms19061770

AMA Style

Li Y, Gong Q, Guo W, Kan X, Xu D, Ma H, Fu S, Liu J. Farrerol Relieve Lipopolysaccharide (LPS)-Induced Mastitis by Inhibiting AKT/NF-κB p65, ERK1/2 and P38 Signaling Pathway. International Journal of Molecular Sciences. 2018; 19(6):1770. https://doi.org/10.3390/ijms19061770

Chicago/Turabian Style

Li, Yanwei, Qian Gong, Wenjin Guo, Xingchi Kan, Dianwen Xu, He Ma, Shoupeng Fu, and Juxiong Liu. 2018. "Farrerol Relieve Lipopolysaccharide (LPS)-Induced Mastitis by Inhibiting AKT/NF-κB p65, ERK1/2 and P38 Signaling Pathway" International Journal of Molecular Sciences 19, no. 6: 1770. https://doi.org/10.3390/ijms19061770

Find Other Styles
Note that from the first issue of 2016, MDPI journals use article numbers instead of page numbers. See further details here.

Article Access Map by Country/Region

1
Back to TopTop